Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Bijuva estradiol and progesterone Vasomotor symptoms associated with menopause Reimburse with clinical criteria and/or conditions Complete
Biktarvy bictegravir/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Bimzelx bimekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Bimzelx bimekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Bimzelx bimekizumab Psoriatic arthritis Reimburse with clinical criteria and/or conditions Complete
Bimzelx bimekizumab Hidradenitis suppurative Received
Blincyto Blinatumomab Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete
Blincyto Blinatumomab MRD+ ALL Resubmission Reimburse with clinical criteria and/or conditions Complete
Blincyto Blinatumomab Acute Lymphoblastic Leukemia (pediatric) Reimburse with clinical criteria and/or conditions Complete
Blincyto Blinatumomab Withdrawn